Titan Pharmaceuticals
 | |
| Public | |
| Traded as | NASDAQ: TTNP |
| Industry | Pharmaceuticals |
| Headquarters | California |
Key people | Sunil Bhonsle |
Number of employees | 13 (June 2015) |
| Website | www.titanpharm.com |
Titan Pharmaceuticals, Inc. is a California biopharmaceutical company developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.
Titan's principal asset is Probuphine,[1] a slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”)[2] for the treatment of opioid addiction or chronic pain. Template:As of 2015, it was in phase 3 trials.[3]
References
- ↑ Probuphine®
- ↑ Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
- ↑ "Probuphine® Program Update". Titan Pharmaceuticals. Retrieved 21 September 2015.
External links
This article is issued from Wikipedia - version of the Tuesday, October 13, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.